We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Structure-Activity Relationship of New Anti-Tuberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters
News

Structure-Activity Relationship of New Anti-Tuberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters

Structure-Activity Relationship of New Anti-Tuberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters
News

Structure-Activity Relationship of New Anti-Tuberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Structure-Activity Relationship of New Anti-Tuberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abstract

During the syntheses and studies of natural iron chelators (mycobactins), we serendipitously discovered that a simple, small molecule, oxazoline-containing intermediate 3 displayed surprising anti-tuberculosis activity (MIC of 7.7 microM, average). Herein we report elaboration of SAR around this hit as well as the syntheses and evaluation of a hundred oxazoline- and oxazole-containing compounds derived from an efficient three step process: 1) formation of beta-hydroxy amides with serine or threonine; 2) cyclization to afford oxazolines; and 3) dehydration to give the corresponding oxazoles. A number of compounds prepared by this method were shown to possess impressive activity against Mycobacterium tuberculosis, extremely low toxicity and therefore high therapeutic indexes, as well as activity against even the more recalcitrant non-replicating form of M. tuberculosis. The uniqueness of their structures and their simplicity should allow them to be further optimized to meet ADME (absorption, distribution, metabolism, excretion) requirements. The syntheses of eight of the most potent in vitro compounds were scaled up and the compounds were tested in an in vivo mouse infection model to evaluate their efficacy before engaging upon more elaborate compound design and optimization.

The article is published online in an NIH Public Access Author Manuscript and is free to access.

Advertisement